INTRODUCTION:

Biologics are medications produced by biological processes or from living cells. These are rather complicated molecules that are typically made up of complex composites of proteins, carbohydrates, nucleic acids, transplantable cells, or tissues^1,2. The treatment of many diseases has undergone a significant change thanks to biological products, especially chronic illnesses involving an overactive immune system or compromised immune surveillance³.

By fusing human constant region domain sequences with murine variable domain sequences, the first humanization strategy produced chimeric antibodies, which had decreased immunogenicity while retaining specificity⁴. The capacity of antibodies to both directly destroy tumour cells and stimulate the host immune system to produce durable effector responses against the tumour makes them unique⁵. An antibody is normally composed of four polypeptide chains, each of which has an amino terminal variable region (s) and are linked together by disulfide bridges or bonds. Each chain has one heavy chain and one light chain⁶. Animals are immunised to produce antibodies, which are then produced by extracting the animal's spleen cells and evaluating titers over a period of many months⁷. Monoclonal antibodies (MAbs) are widely utilised in a variety of diagnostic laboratory procedures and are one of the most potent instruments in fundamental research⁸. Although humanization has lessened the occasionally very high immunogenicity linked to murine MAbs, it has also been demonstrated that so-called human MAbs can occasionally produce antibodies with significant therapeutic effects⁹. A significant number of pharmaceuticals have been directed towards two categories of diseases: immune-inflammatory disorders and cancer. For additional indications, such as haemophilia A, thrombotic thrombocytopenia, recurrent episodes of multiple sclerosis (MS), atopic dermatitis, asthma, the Clostridium difficile infection, migraine, and osteoporosis prevention, an extensive number of monoclonal antibodies have been developed¹⁰. Targeting specific mutations and aberrations in protein structure and expression in a range of diseases and circumstances is made possible by the research and development of MAbs¹¹.

BIOLOGICS:

MAbs are produced by one specific form of immune cell, known as a B cell, and are therefore referred to as "monoclonal."¹ Biotechnology has been a creative tool in medicine, helping to create the intriguing class of medications known as biologics. Medicines are now made in living cells that can be cultivated in vitro rather than in non-living containers¹. Biologics, mainly MAbs and antibody-drug conjugates (ADC), are now considered standard treatments and have been increasingly approved recently. Most of these biotherapeutics are MAbs or proteins produced from MAbs, which can undergo transformation processes such isomerization, oxidation, and deamidation¹². MAbs are proteins with complicated physiochemical characteristics and a molecular weight of about 150 kDa^7,13. IgA, IgD, IgE, IgG, and IgM are the five different kinds of antibodies based on the type of heavy chain⁵. At the moment, IgG is the sole class of antibodies used in MAb therapy^5,14.

Recent discoveries and development of novel therapies have also benefited the biotech company. Customized medication is one of the most revolutionary technologies. For example, CAR T (Chimeric Antigen Receptor Thymus) cell therapy enables individualized patient care by genetically modifying a patient's isolated cells to produce CART cells, which are subsequently grown¹. Muromonab, the first monoclonal antibody, received approval in 1982 as a mouse protein for use in acute organ transplant rejection^15–17. The genesis of Multiple Sclerosis (MS), especially in its early stages, is dominated by immune system-related inflammation of the central nervous system⁸. Biologics are currently being utilized to treat the most severe, chronic, and potentially fatal illnesses, including cancer, immune-related inflammatory diseases, Type 2 diabetes, and infertility. In the future, biologics may also be used to treat other illnesses. However, issues with biologic medication accessibility and pricing outweigh the therapeutic advantages of biologic therapy¹⁸.

Advantage over small molecule drugs:

Biologics have monopolized so many therapies for the most devastating diseases that even people who cannot pay them will always require these medications¹. MAb have high affinity and selectivity towards target; and having half-life of approximately of week to months⁷. Unlike small molecule drugs that may affect various cellular processes, MAbs are designed to engage with specific molecular targets, allowing for a more focused therapeutic approach. Because of their bigger size, monoclonal antibodies cannot pass through the blood-brain barrier; instead, methods like intranasal administration or specific targeting are needed to enable their entry into the brain.

Importance of dug development based on origin:

MAbs represent a class of biopharmaceuticals that have revolutionized the field of medicine. The origin of MAbs, whether murine, chimeric, humanized, or fully human, plays a crucial role in determining their drug properties and suitability for various therapeutic applications. The origin of each individual MAb determines its designation -omab, -ximab, -zumab, and -umab tend to be employed as suffixes that denote, respectively, murine, chimeric, humanized, and human agents¹⁴.

Murine monoclonal antibody as drugs:

The murine MAb was the first to be identified and replicated. This particular type of MAb is produced by isolating B cells from a mouse's spleen and fusing them with an immortal myeloma cell line that does not have the hypoxanthine-guanine-phosphoribo-syltransferase gene¹⁹. Because of their low affinity for the human neonatal Fc receptor (FcRn), murine MAbs have a relatively limited half-life in humans. Additionally, they were not very good at activating effector functions, which are essential for some of the efficiency of MAbs².

Chimeric monoclonal antibody as drugs:

The constant domain of a human MAb have been merged with the antigen-specific variable region of a mouse MAb to create chimeric antibodies. As an outcome, chimeric MAbs having an amino acid makeup that is roughly 65% human were produced². These MAbs have a longer half-life in humans and have lower immunogenicity when compared against their murine counterparts. Despite this, chimeric MAbs nevertheless have a significant tendency to produce anti-drug antibodies¹⁹.

Humanized monoclonal antibody as drugs:

The process of creating humanized monoclonal antibodies involves putting the hypervariable portions of the light and heavy chains from mice onto an antibody framework. As outcome, almost 95% of the compounds are human¹⁹. The antibody is an adapter protein that can bind to a wide variety of antigens because it has binding regions for effector molecules at one end and antigens at the opposite end²⁰. Humanised MAbs are significantly less immunogenic than chimeric MAbs¹¹.

Human monoclonal antibody as drugs:

One of the most widely used methods for creating humanized MAbs is CDR grafting, which Gregory P. Winter first created in 1986²¹. Using an idiotype/anti-idiotype interactions, human MAbs have novel regions in the CDRs that can direct the immune system to respond². When compared to other kinds of monoclonal antibodies, these ones tend to be less antigenic and more well-tolerated. In addition, in contrast to the remaining categories, they seem to stay in the human body's blood¹⁹. The first truly human MAb to be authorized to be used in the treatment of rheumatoid arthritis was Humira (adalimumab) in 2004¹⁶.

Figure 1: Types of antibodies employed and their potential roles as effectors.

The distinctions between murine, chimeric, humanized and human antibodies are displayed in the top portion of the screen. The effector functions are displayed in the next panel. Antagonism: An MAb may interfere with a receptor's ability to bind with its ligand, obstructing signalling. Signalling: By attaching itself to the receptor, the MAb can trigger signal transduction directly. CDC: Complement-dependent cytolysis is the mechanism by which the MAb lyses cells. ADCC: The MAb interacts with an Fc receptor to cause cellular cytolysis by antibody-mediated lysis of the cells. Vehicle: Materials can be delivered to the target tissue via the MAb.

MECHANISM OF ACTION:

Since Kohler and Milstein first proposed the idea of MAbs in 1975, it has undergone significant evolution^7,14,22,23. MAbs work through a variety of ways, including as immune-mediated cell toxicity, vascular disruption, direct cell toxicity, and immune system regulation¹⁴. MAbs targets different Clusters of differentiation (CD), Interleukin (IL), Growth factor receptor, Tumor necrosis factor (TNF) and others factor; which binds and hinders the effect of antigen by deactivating the above mention factors¹⁶. Through the Fc region, MAbs can kill the desired cell by complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC is the destruction of the cells being targeted with antibody linked to their surface; effector cells, such as neoplastic cells (NK cells), bind to the immunoglobulin via the Fc receptor to carry out the lysis⁸.

The defining feature of autoimmune disorders is the activation of autoreactive CD4+ lymphocytes in the peripheral lymph nodes, where T lymphocytes engage in interactions with B lymphocytes and antigen-presenting cells (APCs). Activated T lymphocytes multiply and go into the parenchyma of the affected organ, where they bind to naturally occurring ligands and produce pro-inflammatory chemicals and cytokines that cause impairment of cells and the advancement of the disorder. Blocking and depleting T lymphocytes and/or B lymphocytes, inhibiting the interaction across T cells and APCs, blocking T- and B lymphocytes recruitment, blocking T lymphocyte differentiation or stimulation, and blocking pro-inflammatory cytokines are a few of the mechanisms by which MAbs are used for the treatment of autoimmune disorders⁷.

Figure 1: Different monoclonal antibodies' MOA in MS

Opicinumab facilitates the differentiation of myelin-producing oligodendrocyte precursor cells into myelin-producing oligodendrocytes. Th: T lymphocytes, OLG: Oligodendrocyte, OPC: Oligodendrocyte precursor cell and LINGO-1: Leucine rich repeat and immunoglobin like domain containing protein 1

Numerous MAbs have been created to treat a range of neoplasia, such as solid tumors and blood cancers. The first strategy uses MAbs to destroy cancerous cells by targeting tumor antigens. Growth factor receptors that are excessively expressed in tumor cells, such as EGFR and HER2, are the primary targets for therapeutic MAbs used in chemotherapeutic applications. Because MAbs obstruct these receptors, they also obstruct ligand interaction and signaling, which can slow down tumor development, cause apoptosis, and make tumors more susceptible to treatment^7,23. Compared to patients with a normal immunological system, cancer patients have a lower likelihood of producing antibodies, particularly MAb drugs. Patients receiving MAb therapy may occasionally also receive immune suppression medications, like methotrexate, in an effort to block the immune system's response⁹.

REGULATORY FRAMEWORKS:

Specific guidelines together with clarification queries and reply to papers have been released by the World Health Organisation (WHO), the Food and Drug Administration (FDA), and the European Medicines Agency (EMA)⁶. Beginning in September 2012, the Central Drugs Standard Control Organization (CDSCO) and the Department of Biotechnology, India (DBT) released the first set of "Guidelines on Biologics"³. The WHO's recommendations are followed by Indian and Chinese regulations, while the EMA's recommendations are largely followed by South Africa's and Turkey's country with some variations⁶. For biological substances produced in animal or human cell lines, proving viral safety is a crucial regulatory necessity²⁴. The main recommendation for the preclinical safety assessment of medications generated from biotechnology (pharmaceutical products) is the ICH S6(R1) guideline¹⁰.

A number of popular biological medications are no longer covered by patents or will soon approach expiration, which creates an excellent chance for the pharmaceutical industry to produce biosimilars²⁵. Numerous affluent nations, including the United States, Europe, and Australia, have instituted national biovigilance initiatives. The Biovigilance Programmed of India was started in India by the National Institute of Biologicals and the Indian Pharmacopoeia Commission (IPC)²⁶.

The generic pharmaceutical business in India has taken satisfaction in being the biggest producer and supplier of necessary and life-saving medications²⁷. In the European continent, 15 more biological substances are anticipated to hit the patent cliff in the next five years, making 34 biologics without patents as of 2018¹⁸. The standard for patent eligibility for advances in the biotechnology and pharmaceutical industries has been strengthened in order to deter expanding and fraudulent patenting²⁷. Many pharmaceutical companies now follow a 10-to-12-month timeframe for product development, commencing with the discovery of the lead MAb and ending with the phase 1 investigational new drug application (IND). This is a significant decrease from the 18-month timeframe that was considered standard five or more years ago in pharmaceutical companies²⁸. The procedure development-wise, the majority of research and development is directed on incorporating and enhancing bioprocess techniques in order to boost manufacturing versatility and efficacy for biopharmaceuticals²⁴.

FDA:

After first approval of therapeutic MAb Muromonab-CD3, 136 therapeutic MAbs are approved till December 2021 by FDA²⁹. In 2017, FDA broke its record and approved 17 therapeutic antibodies. In 2018, FDA approved 15 therapeutic antibodies. In 2019, FDA approved 16 therapeutic antibodies. In 2020, FDA approved 13 therapeutic antibodies^29,30. In 2022, FDA approved 16 therapeutic antibodies³¹. The FDA can approve products intended for serious or life-threatening diseases based on the drug's impact on an alternative endpoint that is most likely to forecast a clinical advantage to patients, but a mandatory post-approval investigation is required to confirm that the drug delivers the anticipated clinical advantages to patients³².

CDSCO:

The national regulatory organisation in India that assesses the quality, safety, and efficacy of medications is known as CDSCO. DBT holds the charge of managing the preclinical testing and development of recombinant DNA-derived pharmaceuticals via the Review Committee on Genetic Manipulation (RCGM)³³. The biologics approved by CDSCO are mentioned in Table 1(humanized) and Table 2 (human) from year 2020 to 2023.

Table 1: CDSCO approved Humanized Monoclonal Antibodies drugs for manufacturing in India from 2020

Drug	Name of the manufacture	Indicationandusage	Mechanismof action	Reference
Benralizumab	AstraZeneca Pharma	Asthma	Binds with considerable selectivity to the α-chain region of IL-5R, inhibiting both the signaling it produces and the growth of cell lines.	34
Bevacizumab	Enzene Biosciences	Metastatic carcinoma of the colon or rectum	Binds to Vascular Endothelial Growth Factor, inhibits proangiogenic signaling, and fails to engage with its cell membrane receptors.	35,36
Brolucizumab	Sandroz	Neovascular age related macular degeneration.	Angiogenesis andVascular Endothelial Growth Factor.A inhibitor.	37,38
Crizanlizumab	Sandroz	Reduce frequency of Vasoocclusive crises in Sickle cell anaemia	Prohibits platelets and endothelial cells from interacting with P-selectin glycoprotein by binding to P-selectin.	39,40
Dostarlimab	GSK Pharma India	Mismatch repair deficient recurrent or advanced endometrial cancer	It interacts with the receptor as an inhibitor against Programmed Death Receptor-1, inhibiting its responses to Programmed Death Receptor-L1 and Programmed Death Receptor-L2.	41
Galcanezumab	Eli Lilly and Company	Migraine	Inhibits theCalcitonin Gene Related Peptide ligand from binding to the receptors by engaging to it.	42,43
Infliximab	Pfizer	Crohn's disease, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and ulcerative colitis.	Blockade of soluble and transmembrane cell surface TNFα receptors.	8,10,44
Ixekizumab	Eli Lilly and company	Psoriatic arthritis and Plaque psoriasis	Inhibits the IL-17A and IL-17A/F heterodimer.	10
Mepolizumab	GSK Pharmaceuticals	Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic syndrome	Binds and inactivates the IL-5	45,46
Ocrelizumab	Roche Products	Multiple sclerosis and Primary Progressive Multiple sclerosis	Targets CD20, preserves B-cell reconstitution and immunity while depleting B-cells and aiding in the pathophysiology of Multiple sclerosis.	47,48
Palivizumab	AstraZeneca Pharma	Lower respiratory tract infection caused by Respiratory syncytial virus	Respiratory syncytial virus replication inhibition and direct virus neutralisation.	49
Pembrolizumab	MSD Pharmaceutical	Advanced Renal cell carcinoma, cervical cancer and Metastatic Triple Negative Breast Cancer	Inhibits Programmed Death Receptor, -1 and increases the expression of IL-2 and IL-7.	50
Polatuzumab Vedotin	Roche Product	Untreated diffuse large B-cell malignancies	Binds to CD79b and releases Monomethyl Auristatin E, which stops cell proliferation and triggers apoptosis.	51
Ranibizumab	Sun Pharmaceutical Industries, Sandroz and Zenotech Laboratories	Retinopathy of prematurity and Neovascular age related macular degeneration.	Binds to Vascular Endothelial Growth Factor.A receptor site, preventing it to expressed on surface cells.	52
Romosozumab	Dr. Reddy’s Laboratories	Postmenopausal women with Osteoporosis	Attacks and binds with the Sclerostin protein leads to bone formation and inhibition of Receptor Activator of Nuclear Factor kappa-B.	53
Spesolimab	Boehringer Ingelheim	Generalized Pustular Psoriasis	Inhibit the IL-36R receptor complex.	54
Trastuzumab	AstraZeneca Pharma and Roche Product	Early-stage breast cancer and metastatic HER2 positive breast cancer.	Binds to Epidermal Growth Factor Receptor and HER2, which causes the PI3K pathway to be downregulated and the cell cycle terminates in the G1 phase.	10,55
Vedolizumab	Takeda Biopharmaceuticals	Crohn’s disease and Ulcerative colitis	Binds and blocked α4β7 integrin with MAdCAM-1	56

Table 1: CDSCO approved Human Monoclonal Antibodies drugs for manufacturing in India from 2020

Drug	Name of the manufacture	Indication and usage	Mechanism of action	Reference
Adalimumab	Shilpa Biologicals and Enzene Biosciences	Rheumatoid Arthritis and Severe active ankylosing spondylitis	Blockade of soluble and transmembrane TNFα cell surface receptors.	10,57,58
Daratumumab	Johnson and Johnson	Multiple Myeloma	Immunoglobulin G1 kappa targets CD38, present on hematopoietic cells responsible for cell signaling functions.	19,59
Denosumab	Enzene Biosciences and Reliance life Sciences	Osteoporosis	Aim for Receptor Activator of Nuclear Factor kappa-B Ligand, a polypeptide that serves as the main indicator to encourage the breakdown of bone.	60
Durvalumab	AstraZeneca Pharma	Metastatic Biliary tract cancer	Directed against Programmed Death Receptor -L1, this binding prevents the interaction between Programmed Death Receptor -L1, provide immune-tolerance.	61
Evolocumab	Dr. Reddy’s Laboratories	Hypercholesterolaemia and mixed dyslipidaemia and Atherosclerotic cardiovascular disease.	Aim for Proprotein Convertase Subtilisin/ kexin Type 9, a liver-produced serine protease that attaches to LDL receptors to form a complex that can be degraded by lysosomes.	62
Golimumab	Reliance life Sciences	Active rheumatoid arthritis	Inhibition of transmembrane TNFα cell surface receptors that are soluble.	10,63
Ipilimumab	Bristol Myers Squibb	Renal Cell Carcinoma	Inhibits Cytotoxic T-lymphocyte antigen 4 and stimulate immune and T-lymphocyte	64
Nivolumab	Bristol Myers Squibb	Renal cell carcinoma, cHL, colorectal cancer, urothelial carcinoma, and non-small cell lung cancer.	It interacts with the receptor as an inhibitor against Programmed Death Receptor -1, inhibiting its responses to Programmed Death Receptor, -L1 and Programmed Death Receptor, -L2.	65
Tremelimumab	AstraZeneca Pharma	Unresectable hepatocellular carcinoma	Targeted at the Cytotoxic T lymphocyte Associated Antigen 4	66
Ustekinumab	Reliance life Sciences and Johnson and Johnson	Plaque psoriasis and Crohn’s disease	Inhibits p40 from interacting to the IL-12Rβ1 receptor protein.	8,10

Novel engineering in monoclonal antibodies:

Proteomic investigations of antibodies in bloodstream or bodily fluids are combined with next-generation sequencing (NGS) examination of B cells that encode antibodies in a recently developed method. Thus, proteomics offers priceless insights into the molecular, monoclonal characteristics of human blood antibodies in both well-being and illness². Theoretical techniques have been employed by structure-based computational tools for designing to foresee undesirable outcomes and, as a result, concentrate exclusively on advantageous alternatives. This approach combines molecular biology tools to detect aggregation-prone areas in current or projected protein architectures, which leads to the production of both novel antibodies and bio betters, which are enhanced analogues of original monoclonal antibodies⁴. The ability of sequencing the genetic material of humans and animals has rapidly increased during the last ten years because to NGS technology². Predicting the risk of MAb immunogenicity by preclinical methods is another application of experimental technologies. These consist of many models of animals, T cell stimulation tests, HLA binding, peripheral circulation mononuclear cell activation tests, and DC related assays experiments².

When two IgG strands with different target interaction specificities are combined into one molecule, it becomes possible for the same molecule to bind two target antigens at the same time. This process is known as bispecific (or bifunctional) MAbs. By requiring fewer therapies, bispecific medicines may provide pharmacodynamic collaboration in their action and/or greater comfort for patients. Emicizumab, for instance, binds to two coagulation factors^10,19. CDSCO approved Bispecific MAb are listed in Table 3.

Potential applications:

Since MAbs can specifically target tiny molecules or surfaces of cell components, they have become a significant tool in the treatments of autoimmune illnesses¹⁴. The majority of MAbs target numerous diseases, and the majority target a minimum of one kind of malignancy⁷⁰. Spondyloarthropathies, autoimmune diseases, inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus and oncology illnesses are significant fields of utilisation^14,16. When it comes to treating diseases, MAbs provide several benefits over treatments formed from immune serum. These include fewer variations between lots, a decreased risk of transmission of pathogenic bacteria, and the absence of immunological problems linked to the application of heterologous serum⁷. MAbs have a lot of potential for use in therapeutic and diagnostic medicine, but despite their exceptional specificity, recent experiences with unanticipated side effects and their methods of action have also demonstrated how little we still know about them⁸. Recently, two novel virus-neutralizing MAbs have been licensed for the therapy of mild to moderate COVID-19 infection in outpatients: Bamlanivimab and Casirivimab Idevimab¹¹.

RESULT:

Treatment for diseases requiring an overactive immune system has been greatly altered by biologics, notably monoclonal antibodies. When it comes to treating conditions like cancer, immune-inflammatory illnesses, and thrombotic thrombocytopenia, humanization has improved the treatment outcomes. Cost and accessibility, however, present serious obstacles. By 2028, the biopharmaceutical market is projected to grow to $408.79 billion, with seven businesses holding the lion's share of market share. MAbs cause vascular disruption, direct cell damage, and immune system modification. Apart from all positive and negative effects of MAbs, it is still prominent too available in Indian market and in world with increasing demand.

CONCLUSION:

It is found from the literature that there is large increase in the supply of humanized and human monoclonal antibodies for the development and production of newly discovered diseases and false ailments.This makes the diseases treatment easier and effective to treat it. Also, now their patents are getting expired which make them cheaper to the general public. This yields a great development in the treatment of diseases.

REFERENCES:

1. Makurvet, F. D. Biologics vs. Small Molecules: Drug Costs and Patient Access. Med. Drug Discov. 2021; 9: 100075. https://doi.org/10.1016/j.medidd.2020.100075.

2. Vaisman-Mentesh, A.; Gutierrez-Gonzalez, M.; DeKosky, B. J.; Wine, Y. The Molecular Mechanisms That Underlie the Immune Biology of Anti-Drug Antibody Formation Following Treatment With Monoclonal Antibodies. Front. Immunol. 2020; 11.

3. Joi et. al. Similar Biologics in India: A Story of Access or Potential for Compromise? Indian J. Med. Res. 2020; 152(5): 456–467. https://doi.org/10.4103/ijmr.IJMR_43_18.

4. Santos et. al. Advances and Challenges in Therapeutic Monoclonal Antibodies Drug Development. Braz. J. Pharm. Sci. 2018; 54: e01007. https://doi.org/10.1590/s2175-97902018000001007.

5. Zahavi, D.; Weiner, L. Monoclonal Antibodies in Cancer Therapy. Antibodies. 2020; 9(3): 34. https://doi.org/10.3390/antib9030034.

6. Rahalkar, H.; Cetintas, H. C.; Salek, S. Quality, Non-Clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines. Front. Pharmacol. 2018; 9.

7. Castelli, M. S.; McGonigle, P.; Hornby, P. J. The Pharmacology and Therapeutic Applications of Monoclonal Antibodies. Pharmacol. Res. Perspect. 2019; 7(6): e00535. https://doi.org/10.1002/prp2.535.

8. Lutterotti, A.; Martin, R. Getting Specific: Monoclonal Antibodies in Multiple Sclerosis. Lancet Neurol. 2008; 7(6): 538–547. https://doi.org/10.1016/S1474-4422(08)70110-8.

9. Doevendans, E.; Schellekens, H. Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies. Antibodies. 2019; 8(1): 21. https://doi.org/10.3390/antib8010021.

10. Posner wt. al. Monoclonal Antibodies: Past, Present and Future. In Concepts and Principles of Pharmacology; Barrett, J. E., Page, C. P., Michel, M. C., Eds.; Handbook of Experimental Pharmacology; Springer International Publishing: Cham, 2019; 260: 81–141. https://doi.org/10.1007/164_2019_323.

11. Rawat et. al. An Overview Of Monoclonal Antibodies And Their Therapeutic Applications. Nveo - Nat. Volatiles Essent. Oils J. Nveo. 2021: 4121–4130.

12. Wan, H. An Overall Comparison of Small Molecules and Large Biologics in ADME Testing. ADMET DMPK. 2016; 4: 1. https://doi.org/10.5599/admet.4.1.276.

13. Han, T. H.; Zhao, B. Absorption, Distribution, Metabolism, and Excretion Considerations for the Development of Antibody-Drug Conjugates. Drug Metab. Dispos.2014; 42(11): 1914–1920. https://doi.org/10.1124/dmd.114.058586.

14. Malik, B.; Ghatol, A. Understanding How Monoclonal Antibodies Work. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2023.

15. Kinch, M. S. An Overview of FDA-Approved Biologics Medicines. Drug Discov. Today. 2015; 20(4): 393–398. https://doi.org/10.1016/j.drudis.2014.09.003.

16. Singh et. al. Monoclonal Antibodies: A Review. Curr. Clin. Pharmacol. 2018; 13(2): 85–99. https://doi.org/10.2174/1574884712666170809124728.

17. Hansel et. al. The Safety and Side Effects of Monoclonal Antibodies. Nat. Rev. Drug Discov. 2010; 9(4): 325–338. https://doi.org/10.1038/nrd3003.

18. Dutta et. al. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It Is Not Only About Price! BioDrugs. 2020; 34(2): 159–170. https://doi.org/10.1007/s40259-019-00395-w.

19. Bayer, V. An Overview of Monoclonal Antibodies. Semin. Oncol. Nurs. 2019; 35(5): 150927. https://doi.org/10.1016/j.soncn.2019.08.006.

20. Winter, G.; Harris, W. J. Humanized Antibodies. Immunol. Today. 1993; 14(6): 243–246. https://doi.org/10.1016/0167-5699(93)90039-N.

21. Lu et. al. Development of Therapeutic Antibodies for the Treatment of Diseases. J. Biomed. Sci. 2020; 27(1): 1. https://doi.org/10.1186/s12929-019-0592-z.

22. Descotes, J. Immunotoxicity of Monoclonal Antibodies. mAbs. 2009; 1(2): 104–111. https://doi.org/10.4161/mabs.1.2.7909.

23. Pierpont, T. M.; Limper, C. B.; Richards, K. L. Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy. Front. Oncol. 2018; 8.

24. Somasundaram et. al. Progression of Continuous Downstream Processing of Monoclonal Antibodies: Current Trends and Challenges. Biotechnol. Bioeng. 2018; 115(12): 2893–2907. https://doi.org/10.1002/bit.26812.

25. Sharma et. al. Regulatory Perspective of International Agencies for Development of Biosimilar Products (Monoclonal Antibodies): An Overview. Ther. Innov. Regul. Sci. 2020; 54 (5): 965–977. https://doi.org/10.1007/s43441-020-00112-8.

26. Singh et. al. Biovigilance: A Global Perspective. Perspect. Clin. Res. 2019; 10(4): 155–162. https://doi.org/10.4103/picr.PICR_89_18.

27. Nair, G. G.; Fernandes, A. Patent Policies and Provisions Relating to Pharmaceuticals in India. JIPR. 2014; 191.

28. Kelley, B. Developing Therapeutic Monoclonal Antibodies at Pandemic Pace. Nat. Biotechnol. 2020; 38(5): 540–545. https://doi.org/10.1038/s41587-020-0512-5.

29. Cai, H. H.; Pandit, A. Therapeutic Monoclonal Antibodies Approved by FDA in 2021. Acta Sci. Microbiol. 2022; 81–83. https://doi.org/10.31080/ASMI.2022.05.1166.

30. Cai, H. H. Therapeutic Monoclonal Antibodies Approved by FDA in 2020. Clin. Res. Immunol. 2021; 4(1): 1–2.

31. Cai, H. H.; Pandit, A. A. Journal of Clinical and Experimental Immunology. 2023.

32. Kaplon et. al. Antibodies to Watch in 2023. mAbs15(1): 2153410. https://doi.org/10.1080/19420862.2022.2153410.

33. Rathore, A. Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India. PDA J. Pharm. Sci. Technol. 2012; 66(5): 393–393. https://doi.org/10.5731/pdajpst.2012.00886.

34. FitzGerald et. al. Benralizumab, an Anti-Interleukin-5 Receptor α Monoclonal Antibody, as Add-on Treatment for Patients with Severe, Uncontrolled, Eosinophilic Asthma (CALIMA): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. The Lancet. 2016; 388(10056): 2128–2141. https://doi.org/10.1016/S0140-6736(16)31322-8.

35. Kazazi-Hyseni et. al. Bevacizumab. The Oncologist. 2010; 15(8): 819–825. https://doi.org/10.1634/theoncologist.2009-0317.

36. Krämer, I.; Lipp, H.-P. Bevacizumab, a Humanized Anti-Angiogenic Monoclonal Antibody for the Treatment of Colorectal Cancer. J. Clin. Pharm. Ther. 2007; 32(1): 1–14. https://doi.org/10.1111/j.1365-2710.2007.00800.x.

37. Markham, A. Brolucizumab: First Approval. Drugs. 2019; 79(18): 1997–2000. https://doi.org/10.1007/s40265-019-01231-9.

38. Brolucizumab. https://go.drugbank.com/drugs/DB14864 (accessed 2024-01-22).

39. Crizanlizumab. https://go.drugbank.com/drugs/DB15271 (accessed 2024-01-23).

40. Blair, H. A. Crizanlizumab: First Approval. Drugs. 2020; 80(1): 79–84. https://doi.org/10.1007/s40265-019-01254-2.

41. Costa, B.; Vale, N. Dostarlimab: A Review. Biomolecules. 2022; 12(8): 1031. https://doi.org/10.3390/biom12081031.

42. Lamb, Y. N. Galcanezumab: First Global Approval. Drugs. 2018; 78(16): 1769–1775. https://doi.org/10.1007/s40265-018-1002-7.

43. Galcanezumab. https://go.drugbank.com/drugs/DB14042 (accessed 2024-01-23).

44. Smolen, J. S.; Emery, P. Infliximab: 12 Years of Experience. Arthritis Res. Ther. 2011; 13(1): S2. https://doi.org/10.1186/1478-6354-13-S1-S2.

45. Smith, D. A.; Minthorn, E. A.; Beerahee, M. Pharmacokinetics and Pharmacodynamics of Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody. Clin. Pharmacokinet. 2011; 50(4): 215–227. https://doi.org/10.2165/11584340-000000000-00000.

46. Robinson, D. S. Mepolizumab Treatment for Asthma. Expert Opin. Biol. Ther. 2013; 13(2): 295–302. https://doi.org/10.1517/14712598.2012.725717.

47. Ocrelizumab. https://go.drugbank.com/drugs/DB11988 (accessed 2024-02-05).

48. Hohlfeld, R.; Meinl, E. Ocrelizumab in Multiple Sclerosis: Markers and Mechanisms. Lancet Neurol. 2017; 16(4): 259–261. https://doi.org/10.1016/S1474-4422(17)30048-0.

49. Scott, L. J.; Lamb, H. M. Palivizumab: Drugs1999; 58(2): 305–311. https://doi.org/10.2165/00003495-199958020-00009.

50. Nguyen, C. M.; Jacob, S. E. Pembrolizumab. J. Dermatol. Nurses Assoc. 2017; 9(2): 95. https://doi.org/10.1097/JDN.0000000000000264.

51. Choi; Y.; Diefenbach; C. S. Polatuzumab Vedotin: A New Target for B Cell Malignancies. Curr. Hematol. Malig. Rep. 2020; 15(2): 125–129. https://doi.org/10.1007/s11899-020-00572-7.

52. Blick, S. K. A.; Keating, G. M.; Wagstaff, A. J. Ranibizumab. Drugs. 2007; 67(8): 1199–1206. https://doi.org/10.2165/00003495-200767080-00007.

53. Bandeira, L.; Lewiecki, E. M.; Bilezikian, J. P. Romosozumab for the Treatment of Osteoporosis. Expert Opin. Biol. Ther. 2017; 17(2): 255–263. https://doi.org/10.1080/14712598.2017.1280455.

54. Spesolimab. https://go.drugbank.com/drugs/DB15626 (accessed 2024-02-06).

55. Boekhout, A. H.; Beijnen, J. H.; Schellens, J. H. M. Trastuzumab. The Oncologist. 2011; 16(6): 800–810. https://doi.org/10.1634/theoncologist.2010-0035.

56. Wyant, T.; Fedyk, E.; Abhyankar, B. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab. J. Crohns Colitis. 2016; 10(12): 1437–1444. https://doi.org/10.1093/ecco-jcc/jjw092.

57. Smolen et. al. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N. Engl. J. Med. 2022; 387(8): 715–726. https://doi.org/10.1056/NEJMoa2201302.

58. Mease, P. J. Adalimumab in the Treatment of Arthritis. Ther. Clin. Risk Manag. 2007; 3(1): 133–148. https://doi.org/10.2147/tcrm.s31133.

59. Nooka et. al. Daratumumab in Multiple Myeloma. Cancer2019; 125 (14), 2364–2382. https://doi.org/10.1002/cncr.32065.

60. Denosumab. https://go.drugbank.com/drugs/DB06643 (accessed 2024-01-23).

61. Alvarez-Argote, J.; Dasanu, C. A. Durvalumab in Cancer Medicine: A Comprehensive Review. Expert Opin. Biol. Ther. 2019; 19(9): 927–935. https://doi.org/10.1080/14712598.2019.1635115.

62. Evolocumab. https://go.drugbank.com/drugs/DB09303 (accessed 2024-01-23).

63. Pelechas, E.; Voulgari, P. V.; Drosos, A. A. Golimumab for Rheumatoid Arthritis. J. Clin. Med. 2019; 8(3): 387. https://doi.org/10.3390/jcm8030387.

64. Cameron, F.; Whiteside, G.; Perry, C. Ipilimumab. Drugs. 2011; 71(8): 1093–1104. https://doi.org/10.2165/11594010-000000000-00000.

65. Gunturi, A.; McDermott, D. F. Nivolumab for the Treatment of Cancer. Expert Opin. Investig. Drugs2015; 24 (2): 253–260. https://doi.org/10.1517/13543784.2015.991819.

66. Tarhini, A. A. Tremelimumab: A Review of Development to Date in Solid Tumors. Immunotherapy. 2013; 5(3): 215–229. https://doi.org/10.2217/imt.13.9.

67. John et. al. Amivantamab: A Narrative Drug Review. Cancer Res. Stat. Treat. 2023; 6(2): 261. https://doi.org/10.4103/crst.crst_166_23.

68. Syed, Y. Y. Amivantamab: First Approval. Drugs. 2021; 81(11): 1349–1353. https://doi.org/10.1007/s40265-021-01561-7.

69. Guo et. al. Teclistamab: Mechanism of Action, Clinical, and Translational Science. Clin. Transl. Sci. 2024; 17(1): e13717. https://doi.org/10.1111/cts.13717.

70. Grilo, A. L.; Mantalaris, A. The Increasingly Human and Profitable Monoclonal Antibody Market. Trends Biotechnol. 2019; 37(1): 9–16. https://doi.org/10.1016/j.tibtech.2018.05.014.

Received on 29.11.2024 Revised on 11.04.2025

Accepted on 18.09.2025 Published on 16.03.2026

Available online from March 18, 2026

Research J. Pharmacy and Technology. 2026;19(3):1445-1453.

DOI: 10.52711/0974-360X.2026.00208

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.

BIOLOGICS:

MECHANISM OF ACTION:

REGULATORY FRAMEWORKS:

FDA:

CDSCO:

ISSUES OF CONCERN:

IMMUNOGENICITY:

Infections:

Cytokine storm:

Carcinogenicity:

Novel engineering in monoclonal antibodies:

Potential applications:

RESULT:

REFERENCES:

Drug	Name of themanufacture	Indicationandusage	Mechanismof action	Reference
Amivantamab	Johnson and Johnson	Metastatic non-small cell lung cancer	Binds to extracellular domains of Epidermal Growth Factor Receptor and Mesenchymal Epithelial Transition receptors and limits ligand interaction, further inhibit receptor phosphorylation.	67,68
Teclistamab	Johnson and Johnson	Relapsed and refractory multiple myeloma	Targets to activate T lymphocytes and cause cell lysis by targeting B-cell maturation antigen on myeloma cells.	69